Carl de Franco
Psychiatric/Mental Health · Buffalo, NYNPI 1033777867
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 26.5% of the total. Reporting peaked in 2024 at $13,731 and has fallen 67.0% since, to $4,533 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $69.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$8K
- Indivior Inc.$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$764
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$15,00053%
- Travel & lodging$2,6769%
- Food & beverage$10,44837%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 68 | $7,506 |
| Indivior Inc. | 35 | $7,348 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $5,306 |
| Otsuka America Pharmaceutical, Inc. | 120 | $2,918 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $1,302 |
| Neurocrine Biosciences, Inc. | 18 | $764 |
| E.r. Squibb & Sons, L.L.C. | 20 | $581 |
| Alkermes, Inc. | 18 | $427 |
| Johnson & Johnson | 16 | $424 |
| AbbVie | 11 | $314 |
| Merz North America, Inc. | 9 | $286 |
| Vanda Pharmaceuticals Inc. | 2 | $147 |
| Axsome Therapeutics, Inc. | 2 | $135 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Novo Nordisk | 2 | $124 |
| Dexcom, Inc. | 1 | $122 |
| Avanir Pharmaceuticals, Inc. | 1 | $93 |
| Gilead | 1 | $90 |
| Boehringer Ingelheim | 1 | $88 |
| Luye Pharma (USA) Ltd. | 3 | $59 |
| Orexo US, Inc. | 2 | $30 |
| Biogen | 1 | $27 |
| Lundbeck LLC | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERSERIS$6,653
- UZEDY$5,832
- REXULTI$617
- ABILIFY MAINTENA$602
- Austedo XR$575
- CAPLYTA$482
- INGREZZA$390
- ABILIFY ASIMTUFII$373
- COBENFY$361
- INVEGA SUSTENNA$127
- INVEGA TRINZA$127
- ONPATTRO$125
- Fanapt$125
- DEXCOM G6 TRANSMITTER$122
- VRAYLAR$122
- Auvelity$115
How this compares
$28,288 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PerserisRisperidone | 21 | $59,649 |
| Invega SustennaPaliperidone Palmitate | 17 | $59,391 |
| AristadaAripiprazole Lauroxil | 14 | $42,218 |
| Abilify MaintenaAripiprazole | 13 | $37,760 |
| Haloperidol Decanoate | 52 | $2,618 |
| Ziprasidone Hcl | 13 | $2,341 |
| Thiothixene | 13 | $1,874 |
| Olanzapine OdtOlanzapine | 12 | $1,482 |
| Divalproex Sodium | 33 | $1,028 |
| Haloperidol | 32 | $712 |
| Olanzapine | 15 | $438 |
| Benztropine Mesylate | 26 | $433 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $421 |
| Duloxetine Hcl | 34 | $397 |
| Buspirone Hcl | 14 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Perseris | $7,348 | $59,64921 claims |
| Johnson & JohnsonInvega Sustenna | $424 | $59,39117 claims |
| Alkermes, Inc.Aristada | $427 | $42,21814 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $2,918 | $37,76013 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $23520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Buffalo
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.